PCI Biotech (Norway) Performance
| PCIB Stock | NOK 1.27 0.02 1.55% |
The firm holds a Beta of 0.0761, which implies not very significant fluctuations relative to the market. As returns on the market increase, PCI Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding PCI Biotech is expected to be smaller as well. At this point, PCI Biotech Holding has a negative expected return of -0.0232%. Please make sure to check PCI Biotech's treynor ratio, value at risk, and the relationship between the total risk alpha and maximum drawdown , to decide if PCI Biotech Holding performance from the past will be repeated in the future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days PCI Biotech Holding has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent essential indicators, PCI Biotech is not utilizing all of its potentials. The recent stock price mess, may contribute to short-term losses for the institutional investors. ...more
| Begin Period Cash Flow | 188 M | |
| Total Cashflows From Investing Activities | -341 K | |
| Free Cash Flow | -68.3 M |
PCI |
PCI Biotech Relative Risk vs. Return Landscape
If you would invest 142.00 in PCI Biotech Holding on December 18, 2024 and sell it today you would lose (15.00) from holding PCI Biotech Holding or give up 10.56% of portfolio value over 90 days. PCI Biotech Holding is generating negative expected returns and assumes 6.0981% volatility on return distribution over the 90 days horizon. Simply put, 54% of stocks are less volatile than PCI, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
PCI Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PCI Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as PCI Biotech Holding, and traders can use it to determine the average amount a PCI Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0038
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PCIB |
Estimated Market Risk
| 6.1 actual daily | 54 54% of assets are less volatile |
Expected Return
| -0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average PCI Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PCI Biotech by adding PCI Biotech to a well-diversified portfolio.
PCI Biotech Fundamentals Growth
PCI Stock prices reflect investors' perceptions of the future prospects and financial health of PCI Biotech, and PCI Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PCI Stock performance.
| Return On Equity | -0.74 | |||
| Return On Asset | -0.4 | |||
| Operating Margin | (15.29) % | |||
| Current Valuation | 25.47 M | |||
| Shares Outstanding | 37.33 M | |||
| Price To Earning | (10.88) X | |||
| Price To Book | 1.44 X | |||
| Price To Sales | 18.74 X | |||
| Revenue | 6.27 M | |||
| EBITDA | (85.76 M) | |||
| Cash And Equivalents | 116.12 M | |||
| Cash Per Share | 8.83 X | |||
| Total Debt | 1.28 M | |||
| Debt To Equity | 0.50 % | |||
| Book Value Per Share | 1.70 X | |||
| Cash Flow From Operations | (68.31 M) | |||
| Earnings Per Share | (2.35) X | |||
| Total Asset | 135.98 M | |||
| Current Asset | 48 M | |||
| Current Liabilities | 10 M | |||
About PCI Biotech Performance
By examining PCI Biotech's fundamental ratios, stakeholders can obtain critical insights into PCI Biotech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that PCI Biotech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization technology platform. PCI Biotech Holding ASA was founded in 2000 and is headquartered in Oslo, Norway. PCI BIOTECH operates under Pharmaceuticals And Biosciences classification in Norway and is traded on Oslo Stock Exchange. It employs 11 people.Things to note about PCI Biotech Holding performance evaluation
Checking the ongoing alerts about PCI Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PCI Biotech Holding help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PCI Biotech Holding generated a negative expected return over the last 90 days | |
| PCI Biotech Holding has high historical volatility and very poor performance | |
| PCI Biotech Holding may become a speculative penny stock | |
| The company reported the revenue of 6.27 M. Net Loss for the year was (88.39 M) with profit before overhead, payroll, taxes, and interest of 6.27 M. | |
| PCI Biotech Holding has accumulated about 116.12 M in cash with (68.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.83, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 32.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing PCI Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PCI Biotech's stock is overvalued or undervalued compared to its peers.
- Examining PCI Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PCI Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PCI Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PCI Biotech's stock. These opinions can provide insight into PCI Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in PCI Stock
PCI Biotech financial ratios help investors to determine whether PCI Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PCI with respect to the benefits of owning PCI Biotech security.